Literature DB >> 19569243

Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients.

Jia Zhou1, Tong Ding, Weidong Pan, Ling-Yan Zhu, Lian Li, Limin Zheng.   

Abstract

Immunosuppression mediated by regulatory T cells (Tregs) is a key facilitator of tumor immune evasion, but the source of these Tregs and their contribution to human cancer progression remains unclear. This study investigated the properties of FoxP3(+) Tregs, their prognostic value in patients with hepatocellular carcinoma (HCC) and the underlying mechanisms of FoxP3(+) Treg intratumoral accumulation. In addition to an increased number of circulating FoxP3(+) Tregs, the results also showed that FoxP3(+) Tregs gathered in the tumor site, where they suppressed tissue-derived CD4(+)CD25(-) T-cell activation (p < 0.001), promoting disease progression and poor prognosis in HCC patients (< 0.01). The intratumoral prevalence of FoxP3(+) Tregs was associated with a high density of macrophages (Mvarphi) (p < 0.001). Depletion of tissue Mvarphi thus attenuated the increase of liver FoxP3(+) Treg frequency attributed to in vivo inoculation with hepatoma (p = 0.01), whereas Mvarphi exposed to tumor culture supernatants from hepatoma-derived cell lines increased FoxP3(+) Treg frequency in vitro (p < 0.001). This increase was partially blocked by antiinterleukin-10 antibody (p < 0.01). In conclusion, tumor-associated Mvarphi may trigger a rise of the intratumoral FoxP3(+) Treg population, which in turn may promote HCC progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19569243     DOI: 10.1002/ijc.24556

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  104 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients.

Authors:  Yan-Hong Ni; Liang Ding; Xiao-Feng Huang; Ying-chun Dong; Qin-Gang Hu; Ya-Yi Hou
Journal:  Tumour Biol       Date:  2015-02-11

Review 3.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

4.  Diagnosis: Novel prognostic biomarkers in hepatocellular carcinoma.

Authors:  Roberta W C Pang; Ronnie T P Poon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-13       Impact factor: 46.802

5.  Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection.

Authors:  Kang-jie Chen; Lin Zhou; Hai-yang Xie; Taki-eldin Ahmed; Xiao-wen Feng; Shu-sen Zheng
Journal:  Med Oncol       Date:  2011-06-16       Impact factor: 3.064

Review 6.  Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma.

Authors:  Ai-Bin Zhang; Yi-Gang Qian; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2016 Dec.       Impact factor: 3.066

Review 7.  Immunotherapy of hepatocellular carcinoma.

Authors:  Bruno Sangro; Daniel Palmer; Ignacio Melero
Journal:  Hepat Oncol       Date:  2014-12-11

Review 8.  Myeloid cells in hepatocellular carcinoma.

Authors:  Shanshan Wan; Ning Kuo; Ilona Kryczek; Weiping Zou; Theodore H Welling
Journal:  Hepatology       Date:  2015-07-01       Impact factor: 17.425

9.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Authors:  Guangfu Li; Dai Liu; Timothy K Cooper; Eric T Kimchi; Xiaoqiang Qi; Diego M Avella; Ningfei Li; Qing X Yang; Mark Kester; C Bart Rountree; Jussuf T Kaifi; David J Cole; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

10.  Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.

Authors:  Roniel Cabrera; Miguel Ararat; Yiling Xu; Todd Brusko; Clive Wasserfall; Mark A Atkinson; Lung Ji Chang; Chen Liu; David R Nelson
Journal:  Cancer Immunol Immunother       Date:  2012-12-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.